Breast cancer is the most common malignant
cancer and is the leading cause of
cancer death among females. Molecular imaging is a promising approach for the early detection and staging of
breast cancer as well as for assessing therapeutic responses.
Tumor-targeting
peptides are effective targeting vehicles for molecular imaging. Here, we identified a
breast cancer-targeting
peptide CLKADKAKC (CK3) contains a cryptic C-end rule motif that may mediate its binding to
neuropilin-1 (NRP-1), an attractive therapeutic target which expression was associated with poor outcome of the patients with
breast cancer. Phage CK3 bound to NRP-1-positive
breast cancer cells, which could be inhibited by
peptide CK3 in a dose-dependent manner or by knock-down NRP-1 expression. Consistently, NRP-1 overexpression in cells increased the binding of phage CK3. Furthermore,
peptide CK3 co-localized with NRP-1. Importantly, unlike previously reported NRP-1-targeting
peptides with exposed C-end rule motifs,
peptide CK3 did not penetrate into lungs and heart in vivo, which could make it more clinically applicable. Single-photon emission CT (SPECT) and near-infrared fluorescence (NIRF) imaging showed enrichment of
peptide CK3 to the xenograft
tumors in nude mice. In conclusion, as a novel NRP-1-targeting
peptide,
peptide CK3 could be used for
breast cancer molecular imaging, which may represent a new avenue for
breast cancer diagnostics, staging and assessments of therapeutic response.